Search This Blog

Friday, May 8, 2026

ANI beats, ups guidance

 

ANI Pharmaceuticals beats Q1 estimates with adjusted EPS $2.05, revenue $237.5M, raises 2026 EPS and revenue guidance

  • Q1 2026 revenue rose 20.5% to $237.5 million for the quarter.
  • Raised 2026 revenue, EBITDA and EPS guidance to $1.08–$1.14B revenue and $9.19–$9.69 EPS, according to SEC filing on Q1 2026.
  • Company authorized $100M share repurchase program alongside Q1 2026 results.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)